TheraRadar
Data updated: Mar 29, 2026

ZECUITY

SUMATRIPTAN SUCCINATE
Approved 2013-01-17
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
13
Years on Market

Details

Status
Discontinued
First Approved
2013-01-17
Routes
IONTOPHORESIS
Dosage Forms
SYSTEM

Companies

Teva
Active Ingredient: SUMATRIPTAN SUCCINATE

ZECUITY Approval History

Loading approval history...

What ZECUITY Treats

1 FDA approvals

Originally approved for its first indication in 2013 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZECUITY FDA Label Details

Pro

ZECUITY Patents & Exclusivity

Latest Patent: Oct 2032

Patents (9 active)

US9327114 Expires Oct 8, 2032
US8983594 Expires Nov 19, 2030
US8366600 Expires Apr 21, 2029
US9272137 Expires Sep 7, 2027
US7973058 Expires Apr 12, 2027
US8155737 Expires Apr 12, 2027
US8470853 Expires Apr 12, 2027
US9427578 Expires Apr 12, 2027
US8597272 Expires Apr 12, 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA202278 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.